Here are the 10-Q quarterly reports from CRISPR Therapeutics AG (CRSP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRSP filings page.
CRISPR Therapeutics AG reported third-quarter 2026 revenue of $12.7 million, versus $0.9 million a year earlier, primarily from $12.3 million of deferred Vertex collaboration revenue recognized after Vertex notified the company it would not exercise an option. Net loss was $111.4 million, compared with $106.4 million; nine-month net loss was $325.5 million versus $451.0 million. Nine-month operating cash use was $282.1 million, versus $252.5 million.
At September 30, 2026, cash and cash equivalents were $192.0 million and marketable securities were $2.085 billion. The company issued $600 million of convertible senior notes due March 1, 2031, receiving approximately $585.4 million net. The initial conversion price was approximately $76.56 per share; initially, a maximum of 11,363,580 common shares may be delivered upon conversion. A $12.5 million Sirius development milestone was expensed, with cash payment expected in the fourth quarter of 2026.
In CTX310 Phase 1a, single-course treatment produced reductions sustained through one year; at the highest dose, mean reductions were 79% for ANGPTL3, 48% for triglycerides and 53% for LDL-C. The company recorded an $18.2 million liability for a third-party intellectual-property contract matter; resolution could result in a material charge above the accrual.
CRISPR Therapeutics reported Q2 2026 total revenue of approximately $10.2 million, mainly from collaboration revenue, and a net loss of about $91.2 million (basic and diluted loss per share $0.94). For the first half of 2026, revenue was roughly $11.6 million with a net loss of about $214.1 million.
As of June 30 2026, the company held $2.65 billion in total assets, including substantial marketable securities and cash, and reported total liabilities of $904.2 million. Long-term debt consisted primarily of $600 million of Convertible Senior Notes due 2031, with a net carrying amount of $586.2 million.
The business centers on CRISPR-based therapeutics across hemoglobinopathies, in vivo liver editing, siRNA programs, CAR‑T and regenerative medicine. Key programs include CASGEVY, an approved CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion‑dependent beta thalassemia, and pipeline candidates such as CTX310, CTX611 and next‑generation CAR‑T asset zugocabtagene geleucel.
CRISPR Therapeutics’ Q1 2026 report shows it remains a late‑stage R&D company with substantial cash and a larger capital base. Total revenue was modest at $1.5 million, while operating expenses reached $131.7 million, driven mainly by $68.6 million in research and development and $45.9 million of collaboration expense under its Vertex hemoglobinopathy agreements.
The company reported a net loss of $122.9 million, slightly improved from $136.0 million a year earlier, with basic and diluted loss per share of $1.28 on 96.1 million weighted‑average shares. Operating cash outflow was $108.9 million, partly offset by strong financing inflows.
Liquidity remains a key strength. As of March 31 2026, cash, cash equivalents and marketable securities totaled about $2.44 billion, within total assets of $2.73 billion. During the quarter CRISPR issued $600 million of Convertible Senior Notes due 2031 at a 1.7308% coupon, creating $585.5 million of long‑term debt and net proceeds of about $585.4 million. The added capital supports continued investment across its CASGEVY hemoglobinopathy franchise, in vivo liver programs such as CTX310, siRNA collaboration asset CTX611 and next‑generation CAR‑T candidate zugo‑cel.
CRISPR Therapeutics AG reported a wider quarterly loss as collaboration and R&D spending remained high. For Q3 2025, total revenue was $0.9 million from grants, while operating expenses reached $132.9 million, driven by $58.9 million in research and development and $57.1 million in collaboration expense, net. Net loss was $106.4 million (basic and diluted loss per share $1.17).
Year to date, the company recorded a $451.0 million net loss, including $96.3 million of acquired in‑process R&D tied to the Sirius collaboration. Liquidity remained strong with $286.5 million in cash and cash equivalents and $1,629.2 million in current marketable securities, plus $28.4 million non‑current. Shareholders’ equity stood at $1.916 billion. The company continued equity financing, issuing 5.1 million shares under its 2021 ATM for $286.8 million in net proceeds, and later launched a new 2025 ATM. As of September 30, 2025, 93,872,794 common shares were outstanding.